Professional Documents
Culture Documents
Angiotensin 2 Type-1 Receptor Blockers and Angiotensin I-Converting Enzyme Inhibitors On Survival of Patients With NSCLC.
Angiotensin 2 Type-1 Receptor Blockers and Angiotensin I-Converting Enzyme Inhibitors On Survival of Patients With NSCLC.
Student's Name
Instructor's Name
Course Title
Submission Date
Angiotensin enzyme inhibitors and angiotensin II receptor blocks are prescribed for a
range of od diseases. Hypertension, kidney diseases, and heart failures are various examples.
Vascular homeostasis plays a crucial role in maintaining the renin-angiotensin system. Type 2
proangiogenically. Factor (VEGF) is essential in our test. Experiments on cell culture and animal
studies have indicated that antiproliferative effects at AT1R blockers and angiotensin I
converting enzyme inhibitors in some malignancies. Currently, there are very clinical data that is
from improved non-small cell lung cancer undergo chemotherapy with is first-line platinum-
based. Then the experiment was analyzed upon long time medication with ACEI And ARB.
Lisinopril and Captopril are the only ACE inhibitors that do not need to be activated in the body
Methodology
The coordinates' ethics committee clinically approved the experiment of Ruijin Hospital,
and the followed study methods followed the approved guidelines. As I review this article, Two
hundred twenty-eight patients were used as the sample size. All patients have improved, and
of the patients underwent surgery before chemotherapy and had confirmed stage1,2, or 3. They
had received a first-line based platinum at least once. The hospital used the data of the patients
who had visited the facility, together with information on drugs, dosage, and timing of any
chemotherapy treatment they received. The performance for each patient was put into the record.
Follow-up data was obtained from the patient's file—ACEIs, ARBS, and beta-blockers, calcium
antagonists, and other drugs like antihypertensives. One hundred twelve patients received TKIs
treatment, either as a combination of chemotherapy or initial chemotherapy, and the data were
recorded appropriately.
The treatment results were promising in line with therapy. Survival was calculated from
day 1 to the patient's next visit or death. The aim of the experiment was the intent to give patients
treatment. Os was the period of the test to the end. There is a method known as Meier Kaplan
that we used to calculate a chance of survival. The chi-square test or Fisher's exact test was used
From the first month of 2000 to the last month of 2014, 228 patients with advanced
NSCLC were given treatment with a platinum first line-based chemotherapy, 73 of them being
with different stages has undergone surgery before adjuvant chemotherapy. The sample size of
52 characters of ACEI/ARB and non--ACEI/ARB WERE 249 characters. One hundred twelve of
them received sequential treatment with TKIs. One hundred three affected obtained the
medication for hypertension, and 52 of them appropriated an ACEI with 25 samples or ARB
with 27 sample size. Drugs like antihypertensive and calcium blockers and other drugs have 40,4
and 7 sample sizes, respectively. Specialists listed antihypertensive doses, and I gave ten
patients a combination of the drugs in the facility. All of the patients continued to receive
I evaluated the possible impact of long-term use of ACEIs and ARBs. Among all the patients,
301 showed a significant difference in PFS1. FOR the ACEI/ARB and non-ACEI/ARB, the p-
value was 0.002, with the recipients having a PFS1 longer with 2.4 months than the non-
recipients. The OS between the ACEI/ARB group showed no difference. There was an influence
on patients taking TKIs in PFS between the two different groups of ACEI/ARB. There was a 3.2
months longer PFS for ACEI/ARB recipients than non-recipients. Of the 73 patients who
underwent surgery, it showed no influence in any group. The OS had a significant difference in
patients taking hypertensive drugs between ACEI/ARB. And the two hundred and twenty-eight
patients with advanced NSCLC treated with platinum-based first-line therapy showed a
difference in PFs1 between the ACEI/ARB groups, with a median of 2.1 months longer, but the
OS was the same. Eighty-two patients with advanced NSCLC showed no difference in
Article Summary
The study got some limitations in the preliminary report that ACEI/ARB amplified the
PFS in patients with NSCLC who received TKIs. The clinicians noted that ACEI/s and ARBs
positively impacted PFS and Os, no matter which stage was cancer. Moreover, a larger
population can confirm the hypothesis. This study, however, was not a good model. It missed
significant parts in the medical field, including quality of life, toxicity, and compliance.
Concerns
This study was crucial in the health of the people. Cancer is becoming the number one
killer disease in the world. The research method gives specialists information on treating patients
with the trial and error stage, saving many cancer patients' lives. The study was done well with
minimum concern, just little flaws like not indicating the side effects. The experimenters were
not supposed to assume side effects; they could have recorded them for further research.
Personal Interests
The paper was of interest to me because I have a heart for people. It is sad when I see
patients struggling with cancer, and then we administer a treatment that we are not sure will
work. Assuratity of treatment gives the patients hope. Doctors get motivated to save patients. A
positive outcome is an indication that one day we will fight and win cancer.